The lack of sexual side effects and weight neutrality of Wellbutrin, compared to other antidepressants, is frequently cited as a significant advantage, contributing to higher satisfaction and compliance with treatment
Saxenda (liraglutide) is a GLP-1 receptor agonist administered by subcutaneous injection for weight management in adults with obesity or overweight with comorbidities
Patients should familiarize themselves with the prescription requirements and maintain open communication with their health care provider to understand the details of their treatment plan
In the hindbrain these agonists act to reduce food intake through both satiating and aversive actions
Avoid extreme weight loss methods or crash diets
Real-world data with behavioural support Second Natures peer-reviewed research, published in JMIR Formative Research (2025), showed that semaglutide, combined with registered dietitian support and a structured behaviour change programme, produced an average 19.1% weight loss at 12 months, with 77.7% of participants achieving at least 10% weight loss